HER2/neu peptide vaccine: Interim Phase I data

TapImmune Inc. (OTCBB:TPIV, Seattle, Wash.) said interim data from the first set of 6 patients in an open-label Phase I trial showed that intradermal HER2/neu peptide vaccine led to T cell immune responses against all 4 EGFR2 class II epitopes of the vaccine in 5 patients and T cell immune responses against 3 of the vaccine epitopes in 1 patient. ...